T1	intervention 39 81	docetaxel in combination with capecitabine
T2	total-participants 251 253	83
T3	eligibility 254 298	Patients with at least one measurable lesion
T4	total-participants 589 601	Eighty-three
T5	total-participants 626 628	78
T6	outcome 664 694	overall clinical response rate
T7	outcome 741 765	progressive disease (PD)
T8	outcome 784 801	Efficacy outcomes
T9	outcome 838 851	response rate
T10	iv-bin-percent 874 879	61.8%
T11	iv-bin-abs 881 883	21
T12	intervention-participants 884 886	34
T13	cv-bin-percent 892 897	61.2%
T14	cv-bin-abs 899 901	30
T15	control-participants 902 904	49
T16	outcome 934 953	drug-related deaths
T17	outcome 964 975	Neutropenia
T18	outcome 1031 1052	Grade 3/4 neutropenia
T19	cv-bin-percent 1110 1115	55.1%
T20	cv-bin-abs 1117 1119	27
T21	control-participants 1120 1122	49
T22	iv-bin-percent 1148 1153	32.4%
T23	iv-bin-abs 1155 1157	11
T24	intervention-participants 1158 1160	34
T25	control 540 547	Group B
